Relay Therapeutics
Relay Therapeutics Inc is an American clinical-stage precision oncology company using computational and experimental technologies for drug discovery. The company utilizes its Dynamo platform to analyze protein motion and design targeted small molecule therapies for complex biological targets. Revenue is primarily derived from research collaboration agreements, licensing milestone payments, and investment funding as its drug candidates advance. Core end markets embrace oncology clinical care, targeted cancer research, and precision medicine sectors globally. Relay Therapeutics holds a specialized position in the biotechnology sector through its focus on protein dynamics for drug discovery. The company is headquartered in Cambridge, Massachusetts, and its common stock is listed on the Nasdaq Global Select Market.
9 of the funds FundTelligence covers report a position in Relay Therapeutics.
- Legal name
- Relay Therapeutics Inc
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 9
- Exposure themes
- Cancer, Precision Medicine & Genomics, Precision Oncology, Precision Therapeutics, Treatment, Women's Health
Funds holding Relay Therapeutics
- DNB Bioteknologi — DNB · 1.29 % (full portfolio disclosed, September 2026)
- DNB Fund Women's Health — DNB · 0.94 % (full portfolio disclosed, August 2026)
- Franklin Biotechnology Discovery Fund — Franklin Templeton · 0.66 % (full portfolio disclosed, September 2026)
- T. Rowe Price US Smaller Companies Equity Fund — T. Rowe Price · 0.36 % (full portfolio disclosed, September 2026)
- BlackRock iShares Healthcare Innovation UCITS ETF — BlackRock · 0.29 % (full portfolio disclosed, October 2026)
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.26 % (full portfolio disclosed, October 2026)
- DNB Global Enhanced Small Cap — DNB · 0.03 % (full portfolio disclosed, September 2026)
- Handelsbanken Global SMB Index Criteria — Handelsbanken · 0.02 % (full portfolio disclosed, October 2026)
Showing the 8 largest of 9 funds holding it.